ஆண்டு பெருநிறுவன புதுப்பிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆண்டு பெருநிறுவன புதுப்பிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆண்டு பெருநிறுவன புதுப்பிப்பு Today - Breaking & Trending Today

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
News provided by
Share this article
Share this article
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022 ....

United States , Comunidad Autonoma De Cataluna , Matt Coffey , Oncolytic Reovirus Pelareorep , Jon Patton , Timothy Mccarthy , Kols Aleix Prat , Oncolytics Biotech Inc , National Cancer Institute , Company Contact , Loncode Institute , American Association For Cancer Research , Merck Kga , Leiden University Medical Center , Merck Kgaa , Oncolytics Biotech , Breast Cancer Program , Securities Exchange , Roche Group , Chief Executive Officer , American Association , Cancer Research , Annual Meeting , Mayo Clinic , Key Opinion Leaders , Aleix Prat ,

Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results

Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022
SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. ....

United States , Comunidad Autonoma De Cataluna , Matt Coffey , Oncolytic Reovirus Pelareorep , Jon Patton , Timothy Mccarthy , Kols Aleix Prat , Oncolytics Biotech Inc , National Cancer Institute , Company Contact , Loncode Institute , American Association For Cancer Research , Merck Kga , Leiden University Medical Center , Merck Kgaa , Breast Cancer Program , Securities Exchange , Roche Group , Prnewswire Oncolytics Biotech Inc , Chief Executive Officer , Oncolytics Biotech , American Association , Cancer Research , Annual Meeting , Mayo Clinic , Key Opinion Leaders ,

Oncolytics Biotech Announces Annual General Meeting

Oncolytics Biotech Announces Annual General Meeting
SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ Oncolytics Biotech
Inc. (NASDAQ: ONCY) (TSX: ONC), (the
Company ) today announced that its upcoming 2021 Annual General Meeting (the
Meeting ) will be held virtually at 12:00 p.m. Eastern Daylight Time (ET) on Friday, May 7, 2021. In light of limits on larger gatherings and in the best interest of the health and safety of our employees and shareholders, the Meeting will be held as a virtual-only shareholder meeting. After the Meeting and at the conclusion of shareholder voting, the management team will provide a corporate update and Q&A for institutional investors and analysts, along with a discussion of our first quarter 2021 financial results. ....

United States , Timothy Mccarthy , Company Canada , Oncolytics Biotech Inc , Company Contact , Company Management Information , Securities Exchange , General Meeting , Daylight Time , Management Information Circular , North America , Virtual Meeting , Annual Corporate Update Presentation , Annual Corporate Update , Investor Relations , Securities Exchange Act , ஒன்றுபட்டது மாநிலங்களில் , தீமோத்தேயு ம்க்கார்தீ , நிறுவனம் கனடா , நிறுவனம் தொடர்பு , நிறுவனம் மேலாண்மை தகவல் , பத்திரங்கள் பரிமாற்றம் , ஜநரல் சந்தித்தல் , பகல் நேரம் , மேலாண்மை தகவல் வட்ட , வடக்கு அமெரிக்கா ,

Oncolytics Biotech® Announces Annual General Meeting

Oncolytics Biotech® Announces Annual General Meeting
News provided by
Share this article
SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ Oncolytics Biotech
® Inc. (NASDAQ: ONCY) (TSX: ONC), (the
Company ) today announced that its upcoming 2021 Annual General Meeting (the
Meeting ) will be held virtually at 12:00 p.m. Eastern Daylight Time (ET) on Friday, May 7, 2021. In light of limits on larger gatherings and in the best interest of the health and safety of our employees and shareholders, the Meeting will be held as a virtual-only shareholder meeting. After the Meeting and at the conclusion of shareholder voting, the management team will provide a corporate update and Q&A for institutional investors and analysts, along with a discussion of our first quarter 2021 financial results. ....

United States , Timothy Mccarthy , Company Canada , Oncolytics Biotech Inc , Company Contact , Oncolytics Biotech , Company Management Information , Securities Exchange , General Meeting , Daylight Time , Management Information Circular , North America , Virtual Meeting , Annual Corporate Update Presentation , Annual Corporate Update , Investor Relations , Securities Exchange Act , Health Care Amp Hospitals , ஒன்றுபட்டது மாநிலங்களில் , தீமோத்தேயு ம்க்கார்தீ , நிறுவனம் கனடா , நிறுவனம் தொடர்பு , நிறுவனம் மேலாண்மை தகவல் , பத்திரங்கள் பரிமாற்றம் , ஜநரல் சந்தித்தல் , பகல் நேரம் ,